Sources: US News
The European Medicines Agency conditionally approves the use of the Pfizer anti-COVID-19 oral drug Paxlovid for high-risk adult patients. 2022-01-27
BioNTech CEO Uğur Şahin and Pfizer CEO Albert Bourla both say that their vaccine is likely to be effective against severe disease resulting from the Omicron variant. 2021-11-30
Pfizer and the Medicines Patent Pool sign a global licensing agreement that will allow Pfizer's experimental COVID-19 oral drug Paxlovid to be manufactured under a royalty-free license in 95 low and middle-income countries. 2021-11-16
A late-stage trial of the oral drug Paxlovid conducted by Pfizer shows an 89% reduction in hospitalizations and deaths. 2021-11-5
The government signs an agreement with Pfizer to purchase 40 million doses of the Pfizer–BioNTech vaccine, the Philippines' largest supply agreement for a COVID-19 vaccine. 2021-05-17
The Czech Republic begins a vaccination campaign against COVID-19 using the Pfizer-BioNTech vaccine tozinameran, with Prime Minister Andrej Babiš and World War II veteran Emilie Řepíková among the first people to get vaccinated. 2020-12-27
The Ministry of Public Health approves the authorization of the Pfizer-BioNTech vaccine for emergency use in Qatar. 2020-12-20
The Food and Drug Administration announces that they have formally approved Tozinameran, the COVID-19 vaccine developed by Pfizer and BioNTech. 2020-12-11
Pfizer announces that it has submitted their vaccine for approval in India. 2020-12-5
Mexican Foreign Minister Marcelo Ebrard announces the country has signed agreements with AstraZeneca for 77.4 million, COVAX for 51.57 million, CanSino Biologics for 35 million, and Pfizer for 34.4 million vaccine doses, respectively. The vaccines by Pfizer, AstraZeneca, and the COVAX plan require two doses, whereas the CanSino product requires one dose. 2020-10-13